•Serious
hypoglycemic adverse events slightly more frequent for inhaled
insulin patients than for SQ patients
•More frequent serious hypoglycemic adverse
events for pediatric patients than for adult Type 1
patients
•Rates
of DKA and other SAEs did not differ between treatment
groups
•